Teva Announces Approval of Generic Lexapro Tablets
Jerusalem, Israel, May 22, 2006 - Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Forest Laboratories, Inc.'s Lexapro (Escitalopram Oxalate) Tablets, 5 mg, 10 mg and 20 mg.
Teva's AB-rated Escitalopram Oxalate Tablets are indicated for the treatment of depression.
Teva is currently in patent litigation concerning this product in the U.S. District Court for the District of Delaware. A suit was brought against Teva's subsidiary IVAX in September 2003 involving its paragraph IV certification to U.S. Patent No. RE34,712. A trial was held in March 2006 and the post-trial briefing period ended on May 19th.
Posted: May 2006